Loading…
No business profile yet.
Size Oneness Biotech (4743.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $652M, the 360th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$44.95 on 6 Nov 2026.
Performance Over six months the shares fell 20.7%, against -11.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 37.2% over the last twelve months (peer median +8.0%); the operating margin is -510.1% (peer median 4.8%).
Valuation It trades at 2.10× book value against a peer median of 2.53× (9th cheapest of 21).
Price implies The share price implies a return on equity of about 10.6%; Oneness Biotech delivers 0.6%, so the price asks more than the business earns today.
Next results Next results expected around 19 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$154M | NT$125M | NT$117M | NT$86.8M | NT$1.07B |
| Revenue growth | — | +7% | +35% | -92% | — |
| Gross profit | -NT$232M | -NT$261M | -NT$362M | -NT$382M | NT$552M |
| EBITDA | -NT$462M | -NT$469M | -NT$632M | -NT$648M | NT$250M |
| Net income | NT$60.8M | -NT$1.04B | -NT$1.17B | -NT$1.31B | NT$360M |
| Free cash flow | -NT$179M | -NT$471M | -NT$392M | -NT$485M | -NT$937M |
| Capital expenditure | NT$20.0M | NT$26.5M | NT$53.3M | NT$90.9M | NT$89.2M |
| Total debt | NT$352M | NT$371M | NT$406M | NT$432M | NT$263M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4743.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.6% | -6.6% | 10th highest of 21 |
| 6-month return | -20.7% | -11.6% | 9th lowest of 21 |
| Return on equity | 0.6% | 3.7% | 8th lowest of 21 |
| Price / book | 2.10× | 2.53× | 9th cheapest of 21 |
| Trailing P/E | 357.6× | 22.8× | 2nd most expensive of 14 |
| ROE the price implies | 10.6% | 17.4% | 8th least demanding of 21 |
| ROE delivered | 0.6% | 3.7% | 8th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | 1% | 2.10× | 10.6% | 0.6% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | 1% | 0.98× | 6.7% | 0.8% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 4% | 2.85× | 27.0% | 3.5% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | 1.18× | 10.0% | 4.2% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | -53% | 1.49× | 21.6% | -52.7% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 22% | 3.18× | 24.0% | 22.2% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -19% | 3.88× | 25.8% | -19.2% |
| Sun Pharma Advanced Research SPARC.NS | India | $665M | +16% | +3,141% | 298% | 4.35× | 69.2% | 298.1% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 12% | 1.55× | 10.4% | 11.7% |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $666M | +10% | +40% | -19% | 5.01× | 35.9% | -18.9% |
| Immix Biopharma IMMX | United States | $668M | -17% | n/a | -34% | 2.52× | 11.5% | -34.2% |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | -203% | 4.31× | 17.7% | -203.2% |
| FDC FDC.NS | India | $672M | +4% | +10% | 12% | 2.38× | 31.4% | 12.3% |
| Center Laboratories 4123.TWO | Taiwan | $676M | -28% | +4% | 6% | 1.30× | 4.3% | 6.0% |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -9% | 2.60× | 8.7% | -9.4% |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $678M | -6% | +10% | 20% | 2.54× | 14.3% | 19.6% |
| Earth 4985.T | Japan | $682M | +6% | +6% | 6% | 1.31× | 5.1% | 6.0% |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $682M | -5% | +13% | 2% | 1.99× | 20.2% | 2.4% |
| Nuvectis Pharma NVCT | United States | $683M | +79% | n/a | -67% | 4.24× | 17.2% | -67.0% |
| Mochida Pharmaceutical 4534.T | Japan | $683M | -6% | +15% | 7% | 0.80× | 4.1% | 6.8% |
| Jenkem Technology 688356.SS | China | $686M | -23% | +52% | 4% | 3.44× | 47.3% | 3.9% |